Navigation Links
Instrumentation Laboratory Introduces Fully Automated, Liquid, Ready-to-Use HemosIL® HIT-Ab(PF4-H) Assay in Europe
Date:8/3/2010

BEDFORD, Mass., Aug. 3 /PRNewswire/ -- Instrumentation Laboratory (IL) today announced the release of the new HemosIL HIT-Ab(PF4-H) assay as a European CE IVD Mark product under the European Directive on In Vitro Diagnostic Medical Devices.  Delivering results in minutes, the HemosIL HIT-Ab(PF4-H) assay detects total immunoglobulin against Platelet Factor 4-Heparin complexes, the antibodies associated with the pathology of HIT.  

(Logo:  http://photos.prnewswire.com/prnh/20100803/NE44435LOGO )

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100803/NE44435LOGO )

HemosIL HIT-Ab(PF4-H) is the first, on-demand, fully automated assay for HIT antibody detection on hemostasis testing systems.  Unlike existing manual processes, HemosIL HIT-Ab(PF4-H) assay is liquid and ready-to-use, provides results in minutes and is available 24 hours/day, 7 days/week.   Moreover, the assay is designed exclusively for the ACL TOP® Family of Hemostasis Testing Systems—ensuring ultimate simplicity and efficiency throughout the testing process.  

"Rapid detection of HIT antibodies is critical in the management of Heparin-treated patients suspected of HIT.  HemosIL HIT-Ab(PF4-H) assay provides fast and accurate HIT antibody detection to inform therapeutic decisions when time is critical, " said Giovanni Russi, Director of Worldwide Marketing, Hemostasis Reagents at IL.  "This assay provides significant new efficiencies for our ACL TOP customers in Europe, where, until now, HIT antibody testing has been prohibitively labor-intensive and costly;  and, most importantly, it will contribute to enhanced patient care."

HIT is a severe immune reaction to Heparin that can result in the paradoxical development of a thrombotic event.  One of the most common of all adverse drug effects, due to the sheer volume of patients receiving Heparin therapy (over 12 million patients annually in the US alone), it has a significant impact on anticoagulant management in hospitals worldwide.  If left untreated, patients with HIT may develop serious sequelae, including pulmonary embolism, myocardial infarction, or death.

Instrumentation Laboratory (www.ilus.com), founded in 1959, is a worldwide developer, manufacturer and distributor of in vitro diagnostic instruments, related reagents and controls for use primarily in hospitals and independent clinical laboratories.  The company's product lines include critical care systems, hemostasis systems and information management systems.  IL's GEM® product offerings, part of the critical care line, include the new GEM Premier 3500 with Intelligent Quality Management (iQM®), GEM Premier™ 4000 analyzer, GEMweb Plus Custom Connectivity, and the GEM PCL Plus, a portable coagulation analyzer.  IL's hemostasis portfolio includes the ACL TOP® Family of Hemostasis Testing Systems, fully automated, high-productivity analyzers, including the new ACL TOP 700, the new ACL TOP 700 LAS and the ACL TOP 500 CTS.  IL also offers the new ACL AcuStar™, ACL ELITE® and ELITE PRO, other hemostasis analyzers and the HemosIL® line of reagents, including HIT-Ab(PF4-H).  IL is based in Bedford, Massachusetts.

The Instrumentation Laboratory logo, GEM, iQM, HemosIL, ACL TOP, ACL ELITE, ACL AcuStar and Premier are trademarks of Instrumentation Laboratory Company and/or one of its subsidiaries or parent companies, and may be registered in the United States Patent and Trademark Office and in other jurisdictions.  All other product names, company names, marks, logos, and symbols are trademarks of their respective owners.


'/>"/>
SOURCE Instrumentation Laboratory
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Instrumentation Laboratory Receives FDA Clearance for New Automated Total Bilirubin Assay on GEM Premier 4000 Critical Care Analyzer
2. Instrumentation Laboratory Achieves Record Sales in 2009
3. Patient-Specific Surgical Instrumentation Expedites Total Knee Replacement Procedures
4. Instrumentation Laboratory Receives 510(K) Clearance From FDA and Canadian License for HemosIL(R) D-Dimer HS 500 Assay
5. Amerinet Awards Contract to Instrumentation Laboratory for Critical Care Portfolio
6. Instrumentation Laboratory Installs 2000th ACL TOP(R) System
7. Instrumentation Laboratory Receives FDA Clearance for HemosIL RecombiPlasTin 2G Assay
8. CAP Leaders Stress Need for Oversight of Direct-to-Consumer and Laboratory Developed Tests
9. Agendia to Provide Testimony at Public Meeting on FDA Oversight of Laboratory-Developed Tests
10. OvaGene Oncology Opens New Innovative Gynecologic Cancer Laboratory and Research Facility
11. Dominion Diagnostics Introduces CARD™: The Next-Generation Clinical Laboratory Diagnostics Tool for Addiction Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 27, 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ... whatever measures required to build a strong and stable ... currently listed on the OTC Markets-pink current trading platform. ... CEO, "We are seeing an anomaly in market trading ... only by the Company, but shareholders and market players ...
(Date:6/24/2016)... , June 24, 2016  Consumers have ... and regulators/payers have placed more emphasis on patient ... patient support programs in the pharmaceutical industry have ... medications. Consequently, pharmaceutical companies are focusing on becoming ... are providing products and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
Breaking Medicine News(10 mins):